Liposomal Amphotericin BThird Party Manufacturing in India

Liposomal Amphotericin B works by binding to ergosterol in the fungal cell membrane, creating transmembrane channels that alter cell permeability. It causes leakage of intracellular ions to help the body rapidly eliminate systemic fungal cells. Unlike conventional amphotericin formulations, its lipid bilayer encapsulation selectively channels the active drug to fungal target sites, minimizing uptake by human renal tissues. It is highly effective and well-tolerated, showing a significantly safer kidney profile.

Therapeutic Uses

• Invasive Aspergillosis: Provides definitive treatment for deep, aggressive systemic fungal lung conditions.
• Cryptococcal Meningitis: Crosses blood-brain barriers effectively to resolve critical fungal brain infections in HIV patients.
• Visceral Leishmaniasis: Serves as a premier, high-potency option for treating complex black fever parasitic cases.

Why Manufacturers Choose Liposomal Amphotericin B

This advanced lipid-complexed formulation is a premium critical care medication with steady demand across hematology and transplant units. Developing Liposomal Amphotericin B third party manufacturing in India via Celesta gives brands access to highly complex lipid-nanoparticle formulation tech. Our production facilities are WHO-GMP certified, featuring specialized high-shear homogenization tools and precise liposomal particle sizing systems to ensure uniform drug entrapment and absolute safety.